The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, ...

Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company ...

Since these tissues are not corneal epithelium and do not possess innate limbal stem cells, it would be interesting to perform longitudinal studies to document the long-term restoration of corneal ...

ARLINGTON, Mass. - KALA BIO, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on developing treatments for rare and severe eye diseases, announced a change in its executive leadership on Monday ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the ...

A research team from the Eye & ENT Hospital of Fudan University, China, has developed a novel biocompatible nanoadhesive for ...

Years ago, a young patient's mother told Emily McCourt, MD, associate professor of ophthalmology at the University of ...

The corneal and conjunctival epithelia and the tear film constitute the ocular surface. The conjunctival epithelium contains mucin-producing goblet cells and the mucosal immune defense system.

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.